dsm-firmenich publishes 2025 Integrated Annual Report Press Release dsm-firmenich publishes 2025 Integrated Annual Report Kaiseraugst (Switzerland), Maastricht (Netherlands), February 20, 2026 dsm-firmenich today announces the publication of its Integrated Annual Report (IAR) for 2025, a year during which the company advanced its innovation-led growth agenda, sharpened its strategic profile, and delivered a good performance. The 2025 IAR offers a comprehensive overview of dsm-firmenich’s financial and non-financial progress during the past year. It details the Group’s performance, inclu...
Hyloris provided an update regarding the review of valacyclovir for oral suspension which had a PDUFA target action date of 12 October 2025. It appears that the FDA identified significant inspection observations at the third party manufacturing plant in Greece. The manufacturer confirmed that it is actively implementing its remediation plans. Currently, Hyloris believes that resolution of the manufacturing situation is required to obtain an FDA product approval and is working on a solution. We r...
dsm-firmenich issues €1.5 billion long-term bonds Press Release dsm-firmenich issues €1.5 billion long-term bonds Kaiseraugst (Switzerland), Maastricht (Netherlands), February 17 2026 dsm-firmenich today announces the successful launch of a €1.5 billion dual-tranche bond issuance, consisting of: €750 million 3.00% fixed-rate notes due 2031€750 million 3.75% fixed-rate notes due 2038 The bonds will be issued by DSM B.V. and guaranteed by DSM-Firmenich AG pursuant to the previously established . The proceeds of the new bonds will be used for refinancing of existing bond maturities. ...
The long awaited divestment of ANH disappointed on deal value (EV € 2.2bn, including a potential earn-out of up to € 0.5bn), but creates a group with a much more comprehensive activity and earnings profile. We still appreciate dsm-firmenich for its broad portfolio and market leading positions in consumer-oriented businesses in Nutrition, Health and Beauty. We remind that we have already lowered our target price upon the ANH divestment announcement last week so we maintain our current € 82 target...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.